

Title:

Infection with SARS-CoV-2 as potential achalasia trigger

Authors:

Pilar Ruz Zafra, Carlos Javier García Sánchez, Alberto Pérez Ramírez, Ana Guil Soto, Eduardo Leo Carnerero

DOI: 10.17235/reed.2022.8975/2022

Link: [PubMed \(Epub ahead of print\)](#)

Please cite this article as:

Ruz Zafra Pilar , García Sánchez Carlos Javier, Pérez Ramírez Alberto, Guil Soto Ana , Leo Carnerero Eduardo.
Infection with SARS-CoV-2 as potential achalasia trigger . Rev Esp Enferm Dig 2022. doi:
10.17235/reed.2022.8975/2022.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Infection with SARS-CoV-2 as potential achalasia trigger

- Authors:

- I. Pilar Ruz Zafra. Gastroenterology Department, Hospital Virgen del Rocío, Sevilla, Spain.
- II. Carlos Javier García Sánchez. General and Gastrointestinal Surgery department, Hospital Virgen del Rocío, Sevilla, Spain.
- III. Alberto Pérez Ramírez. Gastroenterology Department, Hospital Virgen del Rocío, Sevilla, Spain.
- IV. Ana Guil Soto. Gastroenterology Department, Hospital Virgen del Rocío, Sevilla, Spain.
- V. Eduardo Leo Carnerero. Gastroenterology Department, Hospital Virgen del Rocío, Sevilla, Spain.

- Author for correspondence: Pilar Ruz Zafra (pruzzafra@gmail.com)

Accepted Article

Achalasia is a chronic esophageal motility disorder with an estimated annual incidence of 1-2 cases per 100,000 people¹, characterized by incomplete relaxation of the lower esophageal sphincter and abnormal peristalsism. The condition results in dysphagia, regurgitation and chest pain complaints. The etiology of idiopathic achalasia remains unknown. From a pathophysiological perspective, it is caused by loss of inhibitory neurons at the esophageal myenteric plexus. Some viruses, including herpes simplex, human papillomavirus and measles virus, have been reported as triggers as viral infection may induce an aberrant immune response, which under appropriate genetic and environmental conditions would lead to loss of esophageal neurons².

We report the case of 66-year-old male with an uneventful history who was admitted for progressive dysphagia leading to complete solid and liquid intolerance over two months. He reported the condition started after mild infection with SARS-CoV-2, which might be causally related or a coincidental finding. Initially, a gastroduodenal barium study suggested achalasia as then did oral endoscopy, which found no mucosal lesions in a esophagus lacking motility and with retained food remnants. The diagnosis was eventually confirmed by high-resolution manometry, which found aperistaltic waves with panesophageal pressurization compatible with type-II achalasia (Figure 1). Lower esophageal sphincter motility could not be assessed because of inability of the probe to pass through. Therapeutic measures first included endoscopic treatment such as botulinum toxin injection and pneumatic balloon injection to avert greater invasiveness while expecting potential regression. Since the patient relapsed after both these techniques, and his performance status was good, he eventually underwent Heller's myotomy surgery with a good clinical outcome.

Within the hypothetical viral etiology of idiopathic achalasia, SARS-CoV-2 might be thought of as a potential triggering agent. Other case reports in the literature seemingly support this^{3,4}. In addition, this virus has been reported as a potential

cause of worsening of immune-mediated gastrointestinal disorders, including gastroparesis⁵. According to our experience, we suggest that, while the viral infection is transient, once neurons are lost the resulting motor disorder is hardly reversible, hence the therapy option should be aimed at achieving the greatest clinical effectiveness according to each patient's health status.

Accepted Article

References:

1. Oude Nijhuis RAB, Zaninotto G, Roman S, Boeckstaens GE, Fockens P, Langendam MW, Plumb AA, Smout A, Targarona EM, Trukhmanov AS, Weusten B, Bredenoord AJ. European guidelines on achalasia: United European Gastroenterology and European Society of Neurogastroenterology and Motility recommendations. *United European Gastroenterol J.* 2020 Feb;8(1):13-33. doi: 10.1177/2050640620903213. PMID: 32213062; PMCID: PMC7005998.
2. Furuzawa-Carballeda J, Aguilar-León D, Gamboa-Domínguez A, et al. Achalasia An Autoimmune Inflammatory Disease: A Cross-Sectional Study. *J Immunol Res.* 2015;2015:729217.
3. Francisco Javier Molano FJ, Zatarain A, Aparicio M et al. Acalasia secundaria a funduplicatura de Nissen. Posible contribución de la infección por SARS-CoV2. *ASENEM* [Internet] 1 Dic 2021. Disponible en: <https://asenem.org/index.php/2021/12/01/acalasia-secundaria-a-funduplicatura-de-nissen-y-posible-contribucion-de-la-infeccion-por-sars-cov2/>
4. Saldaña G, Ribera R, Ciriza de los Ríos C, et al. SARS-CoV2. Possible achalasia trigger?. *UEG Week 2021.*
5. Song J, Bhuta R, Baig K, et al. COVID-19 infection manifesting as a severe gastroparesis flare: A case report. *Medicine (Baltimore).* 2021 Apr 9;100(14).

Figure 1. Postero-anterior and lateral chest x-rays following a gastroduodenal barium study, which show absence of passage through the cardia, a tapered narrowing of the distal end, and proximal dilation. In the lower figure, high-resolution manometry reveals aperistaltic waves with panesophageal pressurization, consistent with type-II achalasia.

Accepted Article

